The NIH RADx Tech initiative was designed to accelerate the development, scale-up, and deployment of innovative point-of-care (POC) and over the counter (OTC) technologies, with a goal of significantly expanding COVID-19 test accessibility and capacity. Over a period of three years, from its April 29, 2020 launch through April 2023, RADx Tech-supported lab, POC, and OTC platforms received 55 Food and Drug Administration (FDA) Emergency Use Authorizations (EUA) and increased U.S. testing capacity by more than 7.8 billion tests. RADx Tech helped drive a paradigm shift from predominantly laboratory-based COVID-19 testing in the early stages of the pandemic, to widely available home and point of care rapid tests. This talk describes key elements of the RADx process and ongoing activities to accelerate the development of more powerful, and accessible diagnostics, across a spectrum of diseases and conditions, that patients can use in home POC settings.
|